Icosavax, Inc.
ICVX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $2 |
| Gross Profit | -$1 | -$1 | -$1 | -$2 |
| % Margin | – | – | – | – |
| R&D Expenses | $17 | $20 | $17 | $16 |
| G&A Expenses | $9 | $9 | $9 | $9 |
| SG&A Expenses | $9 | $9 | $9 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $25 | $29 | $27 | $25 |
| Operating Income | -$25 | -$29 | -$27 | -$25 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $2 | $2 | $2 |
| Pre-Tax Income | -$22 | -$26 | -$25 | -$24 |
| Tax Expense | $0 | $0 | -$2 | -$2 |
| Net Income | -$22 | -$26 | -$23 | -$21 |
| % Margin | – | – | – | – |
| EPS | -0.44 | -0.59 | -0.55 | -0.54 |
| % Growth | 25.4% | -7.3% | -1.9% | – |
| EPS Diluted | -0.44 | -0.59 | -0.55 | -0.54 |
| Weighted Avg Shares Out | 50 | 45 | 41 | 40 |
| Weighted Avg Shares Out Dil | 50 | 45 | 41 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $2 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$25 | -$29 | -$25 | -$25 |
| % Margin | – | – | – | – |